BSE Live
Apr 21, 16:00Prev. Close
26.56
Open Price
24.50
Bid Price (Qty.)
26.10 (5)
Offer Price (Qty.)
27.12 (99)
NSE Live
Prev. Close
Open Price
Bid Price (Qty.)
()
Offer Price (Qty.)
()
| Key Financial Ratios of ANG Lifesciences India (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
| Per Share Ratios | |||||
| Basic EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.39 | |
| Diluted EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.09 | |
| Cash EPS (Rs.) | -4.33 | -1.36 | 6.96 | 44.56 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 | |
| Revenue from Operations/Share (Rs.) | 71.10 | 111.89 | 168.39 | 341.77 | |
| PBDIT/Share (Rs.) | -0.19 | 7.92 | 18.27 | 65.87 | |
| PBIT/Share (Rs.) | -5.37 | 1.51 | 11.11 | 60.20 | |
| PBT/Share (Rs.) | -12.03 | -8.20 | 2.01 | 51.61 | |
| Net Profit/Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 | |
| NP After MI And SOA / Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 | |
| Profitability Ratios | |||||
| PBDIT Margin (%) | -0.26 | 7.07 | 10.84 | 19.27 | |
| PBIT Margin (%) | -7.54 | 1.34 | 6.59 | 17.61 | |
| PBT Margin (%) | -16.91 | -7.33 | 1.19 | 15.10 | |
| Net Profit Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 | |
| NP After MI And SOA Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 | |
| Return on Networth/Equity (%) | -19.40 | -13.29 | -0.30 | 48.12 | |
| Return on Capital Employed (%) | -8.13 | 2.01 | 12.35 | 50.02 | |
| Return on Assets (%) | -5.40 | -4.18 | -0.09 | 13.85 | |
| Total Debt/Equity (X) | 1.26 | 0.91 | 0.81 | 0.92 | |
| Asset Turnover Ratio (%) | 0.39 | 0.56 | 0.77 | 0.00 | |
| Liquidity Ratios | |||||
| Current Ratio (X) | 1.15 | 1.24 | 1.15 | 1.16 | |
| Quick Ratio (X) | 0.78 | 0.91 | 0.85 | 0.94 | |
| Inventory Turnover Ratio (X) | 1.82 | 2.14 | 3.65 | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 2.57 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 2.24 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.43 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.76 | |
| Coverage Ratios | |||||
| Interest Coverage Ratios (%) | -0.03 | 0.94 | 2.01 | 7.67 | |
| Interest Coverage Ratios (Post Tax) (%) | -0.03 | 0.94 | 2.01 | 7.67 | |
| Valuation Ratios | |||||
| Enterprise Value (Cr.) | 106.47 | 122.38 | 163.11 | 313.54 | |
| EV/Net Operating Revenue (X) | 1.15 | 0.84 | 0.74 | 0.88 | |
| EV/EBITDA (X) | -429.30 | 11.83 | 6.84 | 4.59 | |
| MarketCap/Net Operating Revenue (X) | 0.32 | 0.40 | 0.45 | 0.69 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 97.42 | |
| Price/BV (X) | 0.46 | 0.77 | 1.15 | 2.90 | |
| Price/Net Operating Revenue | 0.32 | 0.40 | 0.45 | 0.69 | |
| Earnings Yield | -0.42 | -0.17 | 0.00 | 0.17 |
10.03.2026
ANG Lifescience Consolidated December 2025 Net Sales at Rs 18.73 crore, down 24.25% Y-o-Y
04.12.2025
ANG Lifescience Consolidated September 2025 Net Sales at Rs 26.05 crore, down 20.77% Y-o-Y
27.11.2025
ANG Lifescience Standalone September 2025 Net Sales at Rs 25.97 crore, down 19.24% Y-o-Y
12.06.2025
ANG Lifescience Standalone March 2025 Net Sales at Rs 17.67 crore, down 48.16% Y-o-Y
10.03.2026
ANG Lifescience Consolidated December 2025 Net Sales at Rs 18.73 crore, down 24.25% Y-o-Y
04.12.2025
ANG Lifescience Consolidated September 2025 Net Sales at Rs 26.05 crore, down 20.77% Y-o-Y
27.11.2025
ANG Lifescience Standalone September 2025 Net Sales at Rs 25.97 crore, down 19.24% Y-o-Y
12.06.2025
ANG Lifescience Standalone March 2025 Net Sales at Rs 17.67 crore, down 48.16% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth